| Acromegaly
Signifor LAR vs Somatuline Depot
Side-by-side clinical, coverage, and cost comparison for acromegaly.Deep comparison between: Signifor Lar vs Somatuline Depot with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSomatuline Depot has a higher rate of injection site reactions vs Signifor Lar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Somatuline Depot but not Signifor Lar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Signifor Lar
Somatuline Depot
At A Glance
IM injection
Every 4 weeks
Somatostatin analog
SC injection
Every 4 weeks
Somatostatin analog
Indications
- Acromegaly
- Pituitary-dependent Cushing's disease
- Acromegaly
- Gastro-enteropancreatic neuroendocrine tumor
- Malignant Carcinoid Syndrome
Dosing
Acromegaly Initial dose 40 mg by IM injection once every 4 weeks; may increase to maximum 60 mg every 4 weeks based on response and tolerability. Child-Pugh B: initial dose 20 mg, maximum 40 mg once every 4 weeks. Avoid in Child-Pugh C.
Pituitary-dependent Cushing's disease Initial dose 10 mg by IM injection once every 4 weeks; may increase up to maximum 40 mg once every 28 days based on response and tolerability. Child-Pugh B: initial dose 10 mg, maximum 20 mg once every 4 weeks. Avoid in Child-Pugh C.
Acromegaly 90 mg deep SC injection every 4 weeks for 3 months; adjust thereafter to 60-120 mg every 4 weeks based on GH and/or IGF-1 levels; controlled patients may extend to 120 mg every 6 or 8 weeks. Starting dose reduced to 60 mg every 4 weeks in moderate or severe renal or hepatic impairment.
Gastro-enteropancreatic neuroendocrine tumor, Malignant Carcinoid Syndrome 120 mg deep SC injection every 4 weeks; if already receiving treatment for GEP-NET, do not administer an additional dose for carcinoid syndrome.
Contraindications
—
- History of hypersensitivity to lanreotide (including angioedema and anaphylaxis)
Adverse Reactions
Most common (>=5%) Hyperglycemia, diabetes mellitus, diarrhea, cholelithiasis, headache, nausea, abdominal pain, fatigue, alopecia, sinus bradycardia, nasopharyngitis, blood creatine phosphokinase increased
Serious Hyperglycemia, ketoacidosis, bradycardia, QT prolongation, liver test elevations, cholelithiasis and complications, pituitary hormone deficiency, steatorrhea and malabsorption of dietary fats
Postmarketing Cholelithiasis resulting in complications including cholecystitis and cholangitis, sometimes requiring cholecystectomy
Most common (>5%) Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, loose stools, cholelithiasis, injection site reactions, musculoskeletal pain, arthralgia, headache, hyperglycemia, hypertension, dizziness
Serious Cholelithiasis and complications of cholelithiasis, hyperglycemia and hypoglycemia, cardiovascular abnormalities, thyroid function abnormalities, steatorrhea and malabsorption of dietary fats
Postmarketing Pancreatic exocrine insufficiency, steatorrhea, cholecystitis, cholangitis, pancreatitis, angioedema, anaphylaxis, injection site abscess
Pharmacology
Pasireotide is a somatostatin analog (cyclohexapeptide) that binds with high affinity to somatostatin receptor subtypes SSTR1, 2, 3, and 5, inhibiting GH secretion in acromegaly and ACTH secretion in Cushing's disease via SSTR2 and SSTR5 activation, leading to decreased cortisol secretion.
Lanreotide is a synthetic octapeptide analog of natural somatostatin with high binding affinity for somatostatin receptors SSTR2 and SSTR5; it inhibits growth hormone and IGF-1 secretion, reduces carcinoid syndrome mediators (urinary 5-HIAA), and suppresses various endocrine, neuroendocrine, exocrine, and paracrine functions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Signifor Lar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Somatuline Depot
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Signifor Lar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Somatuline Depot
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Signifor Lar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Somatuline Depot
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acromegaly: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Acromegaly: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Signifor LarView full Signifor Lar profile
Somatuline DepotView full Somatuline Depot profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.